Advanced Filters
noise

pulmonary-arterial-hypertension Clinical Trials

A listing of pulmonary-arterial-hypertension medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Found 78 clinical trials
D David Ptashnik, MS

Xenon MRI Pulm Hypertension

The overall objective outlined in this study is to determine how pulmonary vascular remodeling in PAH at a cellular and pathological level is associated with changes in gas exchange physiology and hemodynamics (monitored with 129Xe MRI/MRS) and how these signals change with disease progression or treatment.

18 - 75 years of age All Phase 2

Anti-CD20 Antibodies for Treatment of SLE-PAH

This is a prospective, single-arm, single-center, explorative clinical trial to evaluate the effect of Rituximab on disease progression in subjects with SLE-PAH receiving concurrent stable-dose standard medical therapy. The study will focus on assessment of clinical response and safety measures longitudinally. In addition, the biomarker of treatment efficacy with Rituximab …

18 - 65 years of age All Phase 4
L Laurie Hogl

Repurposing Valsartan May Protect Against Pulmonary Hypertension

This is a Phase 2, single-center, randomized placebo controlled trial of valsartan (an angiotensin receptor blocker) in adults with pulmonary arterial hypertension. The study will evaluate the safety and clinical efficacy of a 24-week course of valsartan.

18 - 80 years of age All Phase 2
周胜男

CD19-BCMA CART Cell Therapy for Refractory SLE-LN, SSc, and pSS-PAH

This is a single-center, open-label, non-randomized, single-arm clinical trial. Patients with refractory lupus neritis (SLE-LN), systemic sclerosis (SSc), and primary Sjogren syndrome combined with pulmonary artery hypertension (pSS-PAH) receive CD19-BCMA CAR T cell therapy. The primary objective is to prospectively assess the safety of CD19-BCMA CAR T cell therapy in …

6 - 65 years of age All Phase 1/2
A Ashley Nelson, MD

: Vascular Function in Health and Disease

Many control mechanisms exist which successfully match the supply of blood with the metabolic demand of various tissues under wide-ranging conditions. One primary regulator of vasomotion and thus perfusion to the muscle tissue is the host of chemical factors originating from the vascular endothelium and the muscle tissue, which collectively …

18 years of age All Phase 1
D David Ptashnik, MS

Pulmonary Hypertension SOLAR

The main goal of this study is to develop a noninvasive signature for pulmonary vascular remodeling in Group 3 PH patients, using hyperpolarized 129Xe magnetic resonance imaging (129Xe MRI). Such a signature may identify Group 3 PH responders to PAH-specific therapies. PAH's unique 129Xe MRI signature has been shown in …

18 years of age All Phase 2

A Study to Learn About the Treatment LTP001 in Healthy Participants (Part A) and in Participants With PAH (Part B)

A study to learn about the treatment LTP001 in healthy participants (Part A) and in participants with PAH (Part B)

18 - 100 years of age All Phase 1/2

Hormonal, Metabolic, and Signaling Interactions in PAH

Our hypothesis is that optimal treatment of the dysfunctional metabolic pathways which underlie PAH will improve pulmonary vascular function and consequences of the disease.

- 90 years of age All Phase N/A
S Shaoliang Chen, MD

National Registry and Cohort Study of Pulmonary Vascular Disease

This is a observational、multicenter, prospective cohort study for patients with pulmonary hypertension (PH). The purposes of this study were to evaluate the etiology、clinical characteristics、treatment modalities, and outcomes of patients with PH;also to set up registration system of PH in China, to build a database of Chinese PH, to establish a …

years of age All Phase N/A
P Principal Investigator

Pediatric Pulmonary Hypertension Network (PPHNet) Informatics Registry

Patients are being asked to be in this research study because medical researchers hope that by gathering information about a large number of children with pulmonary hypertension over time, their understanding of the disease process will increase and lead to better treatment. Investigators believe that pulmonary hypertension in children is …

1 - 21 years of age All Phase N/A

Simplify language using AI